Drug intelligence / Profile preview

AK117 + AK112 + nab-paclitaxel + paclitaxel

Development stage: Unknown
Lead developer: Kangfang Sainuo Pharmaceutical
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Intravenous

Overview

This combination consists of four agents: Ligufalimab (AK117), a humanized IgG4 monoclonal antibody that blocks the CD47-SIRPα interaction to enable macrophage-mediated phagocytosis of tumor cells; Ivonescimab (AK112), a bispecific monoclonal antibody targeting PD-1 and VEGF-A to simultaneously inhibit two pathways involved in tumor immune evasion and angiogenesis; nab-paclitaxel, a nanoparticle albumin-bound formulation of the chemotherapy agent paclitaxel, and paclitaxel, a microtubule inhibitor. The combination is designed to synergistically engage the innate and adaptive immune systems alongside cytotoxic chemotherapy to treat advanced malignancies, and is being investigated in clinical trials for solid tumors, including gastrointestinal, hematological, and head and neck cancers[1][5][7].

Other names: Ligufalimab (AK117)Ivonescimab (AK112)albumin-bound paclitaxel (nab-paclitaxel)paclitaxel

Targets

TUBB (Tubulin (alpha and beta subunits))CD47 (Cluster of Differentiation 47)PDCD1 (Programmed cell death protein 1 receptor)VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on AK117 + AK112 + nab-paclitaxel + paclitaxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AK117 + AK112 + nab-paclitaxel + paclitaxel.

Explore the full profile